Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Read Article
News
2024
2023
Archive
Search news articles
March 11, 2021
Nouscom Receives Approval to Begin Phase 1B Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy
March 9, 2021
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region
March 2, 2021
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021
Impel Neuropharma Announces Key Management Team Appointments as Company Advances Toward Commercialization in 2021
March 1, 2021
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
March 1, 2021
Pear Therapeutics Announces Second Closing of Series D Financing
February 26, 2021
Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
February 24, 2021
Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O in Treating Opioid Use Disorder
February 24, 2021
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
February 22, 2021
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
« Previous Page
1
…
10
11
12
13
14
…
16
Next Page »